News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Daily News FDA Approves Aprocitentan for Inadequately Controlled Hypertension Michael O'Riordan March 20, 2024
News Daily News High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention Michael O'Riordan February 29, 2024
News Daily News High Lp(a) Levels Harmful in Patients With and Without ASCVD Michael O'Riordan February 27, 2024
News Daily News One in Three Overweight MI Patients May Benefit From Semaglutide Todd Neale February 26, 2024
News Daily News Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds L.A. McKeown February 23, 2024
News Daily News Low Bleeding Profile With Asundexian Seen in Pooled Analysis L.A. McKeown February 13, 2024
News Conference News ISC 2024 MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone Todd Neale February 08, 2024
News Daily News Injectable Semaglutide Shortage Forces Physicians to Pivot Todd Neale February 05, 2024
News Daily News Less Is More: Lp(a) Much More Atherogenic Than LDL Michael O'Riordan January 16, 2024
News Daily News FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions Todd Neale January 12, 2024
News Daily News Top General Cardiology and CVD Prevention News of 2023 Yael L. Maxwell January 03, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2023 Caitlin E. Cox December 28, 2023
News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data Yael L. Maxwell December 13, 2023
News Daily News Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk Todd Neale December 12, 2023